Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease

Authors

Dimitra G. Georganopoulou, Northwestern University
Lei Chang, Northwestern University
Jwa Min Nam, Northwestern University
C. Shad Thaxton, Northwestern University
Elliott J. Mufson, Rush University Medical Center
William L. Klein, Northwestern University
Chad A. Mirkin, Northwestern University

Document Type

Article

Abstract

The recently developed ultrasensitive bio-barcode assay was used to measure the concentration of amyloid-β-derived diffusible ligands (ADDLs), a potential soluble pathogenic Alzheimer's disease (AD) marker, in the cerebrospinal fluid (CSF) of 30 individuals. ADDL concentrations for the subjects diagnosed with AD were consistently higher than the levels in the CSF taken from nondemented age-matched controls. Studies of ADDLs or for any other potential pathogenic AD markers in CSF have not been possible because of their low concentration in CSF (<1 pM). This study is a step toward a diagnostic tool, based on soluble pathogenic markers for the debilitating disease.

Publication Date

2-15-2005

Publication Title

Proceedings of the National Academy of Sciences of the United States of America

ISSN

00278424

Volume

102

Issue

7

First Page

2273

Last Page

2276

PubMed ID

15695586

Digital Object Identifier (DOI)

10.1073/pnas.0409336102

Recommended Citation

Georganopoulou, Dimitra G.; Chang, Lei; Nam, Jwa Min; Thaxton, C. Shad; Mufson, Elliott J.; Klein, William L.; and Mirkin, Chad A., "Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease" (2005). Translational Neuroscience. 1877.
https://scholar.barrowneuro.org/neurobiology/1877